Cogent Biosciences reported statistically significant improvements in non-advanced systemic mastocytosis symptoms from their Phase 2 and Phase 3 trials of bezuclastinib, a KIT D816V tyrosine kinase inhibitor. The results met primary endpoints including patient-reported symptom relief and biomarkers of mast cell burden. The company is targeting an NDA submission by year-end. Market analysts see bezuclastinib as a potential competitor to Blueprint Medicines’ Ayvakit. The data has driven positive investor response.